Core Points - Mullen Automotive Inc. will implement a 1-for-100 reverse stock split effective June 2, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 [1][2][3] - The reverse stock split will reduce the number of outstanding shares from approximately 80 million to about 800 thousand shares [5] - The reverse stock split will not change the par value of the common stock or the authorized number of shares [4] Company Overview - Mullen Automotive is an electric vehicle manufacturer based in Southern California, with two production plants located in Tunica, Mississippi, and Mishawaka, Indiana [7] - The company began commercial vehicle production in August 2023 and has certified models available for sale in the U.S. as of January 2024 [7] - Mullen Automotive acquired Bollinger Motors in September 2022, which has launched its Class 4 electric truck production [8]

DUBAI, United Arab Emirates, May 29, 2025 (GLOBE NEWSWIRE) -- Micropolis Holding Co. (“Micropolis” or the “Company”) (NYSE: MCRP), a pioneer in unmanned ground vehicles and AI-driven security solutions, today announced it will participate in a fireside chat at Maxim Group’s 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow, to be held from June 3-5, 2025. Virtual Conference Fireside ChatDate & Time: Tuesday, June 3, 2025, 9:30 a.m. ETSpeakers: Fareed Aljawhari, Founder & CEO and Dzmi ...

Flywire recognized for its superior software and payments capabilities and extensive client footprint across luxury travel providers around the worldBOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Flywire Corporation (NASDAQ: FLYW) (Flywire), a global payments enablement and software company, announced that it has been accepted into Virtuoso®’s exclusive portfolio of luxury travel partners, comprising 2,300 preferred suppliers in 100 countries. Inclusion in Virtuoso will provide Flywire new sales and marketing opp ...

IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- via IBN -- ECGI Holdings Inc. (OTC: ECGI), a diversified holding company focused on viticulture, equestrian markets, and emerging innovation, today announced the launch of Uplist Ventures (uplist.vc), a new initiative to identify, support, and scale overlooked startups with the potential to enter public markets. Uplist Ventures will invest in pre-seed through Series B companies, with a preferred focus on those at the Series A and B stages. The firm is targeti ...

Private cloud now rated as a strategic equal to public cloud, driven by cost predictability, GenAI requirements, and trust in delivering on security and compliance needs 53% surveyed say private cloud is their top priority for deploying new workloads over the next three years84% use private cloud for both traditional enterprise apps and modern, cloud-native workloads PALO ALTO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Private clouds are no longer playing catch-up, and public clouds are no longer the default ...

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonistsInternally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing EMERYVILLE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for ...

A Media Snippet accompanying this announcement is available in this link. NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, has once again been named the Official Photographer of the Tribeca Festival, renewing a longstanding partnership with the foremost outlet for independent storytellers. For the sixteenth consecutive festival, Getty Images’ award‑winning entertainment photographers and videographers will capture high‑qualit ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced the exercise of outstanding warrants to purchase 400,000 ordinary shares of the Company at an exercise price of $5.00 per warrant. The warrants were initially issued to investors at the time of the consummation of the Company’s initial public listing on Nasdaq. In connection with the exercise of the warrants, and pursuant to th ...

First-of-Its-Kind Deal Deepens Intermex’s Connection to Soccer and Latino Communities Across Southern CaliforniaLOS ANGELES and MIAMI, May 29, 2025 (GLOBE NEWSWIRE) -- The reigning 2024 MLS Cup champion LA Galaxy and their home stadium, Dignity Health Sports Park (DHSP), have launched a new partnership with International Money Express, Inc. (NASDAQ: IMXI) (Intermex), a leading money remittance provider to Latin America and the Caribbean. The multiyear agreement, brokered by AEG Global Partnerships, makes In ...

Core Insights - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [1][2] - The company will present at the GBA1 Meeting 2025 on June 5, 2025, with a focus on its lead drug candidate, GT-02287, for treating Parkinson's disease [1][2] - Gain's innovative Magellan™ platform is designed to accelerate drug discovery for various difficult-to-treat disorders, including neurodegenerative diseases and rare genetic disorders [3] Company Overview - Gain Therapeutics is engaged in the discovery and development of allosteric therapies, with GT-02287 currently in a Phase 1b clinical trial for Parkinson's disease [2] - The company has additional potential applications for GT-02287 in treating Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease [2] - Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors [2] Presentation Details - The oral presentation is scheduled for June 5, 2025, at 11:20 p.m. EST, presented by Dr. Jonas Hannestad, Chief Medical Officer of Gain Therapeutics [2]